M&A - Regencell (BVI) Ltd

Form Type: SCHEDULE 13D/A

Filing Date: 2025-03-13

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390025023407

Filing Summary: This Amendment No. 6 to Schedule 13D provides updates about Regencell (BVI) Limited's acquisition of ordinary shares in Regencell Bioscience Holdings Limited. Between July 26, 2022, and August 27, 2024, Regencell (BVI) Limited purchased an additional 7,245 Ordinary Shares for $89,765.55. The document details a significant transaction on March 10, 2025, where Regencell (BVI) Limited entered into a Sale and Purchase Agreement to acquire 652,982 Ordinary Shares at an aggregated price of $6,203,329 ($9.50 per share). The funding for this purchase was sourced from Mr. Yat-Gai Au's personal funds. Closing is anticipated around March 13, 2025. The amendment also states that the Reporting Persons have no current plans that would significantly affect the company’s structure or operations.

Document Link: View Document